Cobimetinib tablets 20mg/tablet, 63 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• New primary malignancies (cutaneous and noncutaneous): Patients should be monitored for new malignancies before starting treatment, during treatment, and up to 6 months after the last dose of LuciCob.
• Bleeding: Serious bleeding events may occur during LuciCob treatment. Signs and symptoms of bleeding should be monitored.
• Cardiomyopathy: Patients treated with LuciCob in combination with vimofenib have an increased risk of cardiomyopathy compared with vimofenib alone. The safety of LuciCob in patients with reduced left ventricular ejection fraction (LVEF) has not been determined. LVEF should be assessed before treatment, one month after treatment, and every 3 months thereafter, and during LuciCob treatment.
• Serious skin reactions: Serious rashes should be monitored. LuciCob should be interrupted, dose reduced, or discontinued.
• Serous retinopathy and retinal vein obstruction: Perform regular eye examinations and check for any visual impairments. LuciCob should be permanently discontinued for retinal vein occlusion (RVO).
• Hepatotoxicity: Liver laboratory results should be monitored during treatment and when clinically indicated.
• Rhabdomyolysis: Regularly and when clinically indicated, creatine phosphokinase levels should be monitored for signs and symptoms of rhabdomyolysis.
• Severe photosensitivity: Patients are advised to avoid sunlight.
• Embryo-fetal toxicity: May cause damage to the fetus. Women of childbearing age are advised to be aware of the potential risks to the fetus and to take effective contraceptive measures.

Medication risks

Adverse Reactions
Unresectable or metastatic melanoma: The most common adverse effects (≥ 20%) of LuciCob are diarrhea, photosensitivity, nausea, fever, and vomiting. The most common (≥ 5%) grade 3-4 laboratory abnormalities include elevated glutamyltransferase (GGT), elevated creatine kinase (CPK), hypophosphatemia, elevated alanine aminotransferase (ALT), lymphopenia, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, and hyponatremia.
Tissue cell tumors: The most common adverse reactions (≥ 20%) are acne-like dermatitis, diarrhea, infection, fatigue, nausea, edema, dry skin, maculopapular rash, itching, dyspepsia, vomiting, dyspnea, and urinary tract infections. The most common (≥ 5%) grade 3-4 laboratory abnormalities include: hyponatremia, elevated serum creatine phosphokinase, hypokalemia, elevated serum creatinine, elevated aspartate aminotransferase, hypocalcemia, lymphopenia, leukopenia Less, anemia.